Sanofi beefing up diabetes pipeline, sees growth returning - Reuters

Sanofi beefing up diabetes pipeline, sees growth returning Reuters The company had previously forecast diabetes revenue to shrink by 4 to 8 percent a year on average over 2015-2018 as its patent-expired Lantus insulin is being squeezed by pricing pressure in the United States, the world's-largest health market ... and more »

from diabetes - Google News